Appendiceal Mucinous NeoplasmRare diseaseDrugPhase 2
What this study is
This is a pilot, open-label clinical trial determining the feasibility of metformin therapy in subjects with pseudomyxoma peritonei (PMP) secondary to appendiceal mucinous neoplasms (AMNs).
What's being tested
- Metformin
Intervention · DRUG
Given PO
Study details
- Official title
- Use of Metformin in Patients With Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms
- Sponsor
- University of California, Irvine
- Conditions
- Appendiceal Mucinous Neoplasm · Pseudomyxoma Peritonei
- Enrolling
- 15 people
- Starts
- 2026-06-18
- Est. completion
- 2029-07
- Design
- Open-label, single group, Phase 2
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Patients with clinical diagnosis of pseudomyxoma peritonei (PMP) secondary to presumed appendiceal mucinous neoplasms (AMNs) with recurrent/refractory disease s/p cytoreductive surgery(CRS)/hyperthermic intraperitoneal chemotherapy (HIPEC), unresectable disease, or without planned CRS/HIPEC
- Age ≥18 years
- ECOG performance status ≤2
You can't join if
- Patients with a clinical diagnosis of PMP secondary to presumed AMNs with resectable disease who are planned to undergo CRS/HIPEC
- Patients currently taking metformin for another medical indication
- Patients with a prior adverse event to administration of metformin
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openChao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California, United States
- Oliver Eng, MD · Contact877-827-8839ucstudy@uci.edu
Recruiting
Study team
Sponsor
University of California, Irvine
Study ID STUDY00000747
Principal investigator
Oliver Eng, MD
Chao Family Comprehensive Cancer Center
CONTACT
Chao Family Comprehensive Cancer Center University of California, Irvine
CONTACT
University of California Irvine Medical
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.